化学性质:
规格 | 2mg 5mg 10mg 50mg 100mg 200mg |
CAS | 152658-17-8 |
别名 | N/A |
化学名 | N/A |
分子式 | C28H33ClN2O5 |
分子量 | 513.03 |
溶解度 | DMSO: 33.33 mg/mL (64.97 mM) |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice |
产品描述:
Nalfurafine hydrochloride is a κ-opioid agonist and an anti-itch drug approved in
In mice with experimental dry skin, nalfurafine abolished spontaneous scratching but had no effect on alloknesis[1]. A single administration of subcutaneous TRK-820 significantly increased spontaneous ipsilateral rotational behavior of hemi-parkinsonian rats at 30 μg/kg though the efficacy is moderate and also significantly inhibited L-DOPA-induced dyskinesia at 10 and 30 μg/kg; this inhibition is reversed in the presence of nor-binaltorphimine, a kappa opioid receptor antagonist[2]. TRK-820 dose-dependently inhibited phencyclidine-induced rat hyperlocomotion. TRK-820 dose-dependently attenuated the biochemical changes of both dopamine and serotonin in the prefrontal cortex of rats treated with phencyclidine without affecting their basal levels in normal rats[3].
[1]. Akiyama T, et al. Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice. Acta Derm Venereol. 2015 Feb;95(2):147-50. [2]. Ikeda K, et al. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease. Eur J Pharmacol. 2009 Oct 12;620(1-3):42-8. [3]. Yoshikawa S, et al. Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models. Eur J Pharmacol. 2009 Mar 15;606(1-3):102-8.
特别提醒:
1. 本产品仅供科研使用。请勿用于医药、临床诊断或治疗,食品及化妆品等用途。请勿存放于普通住宅区。
2. 为了您的安全和健康,请穿好实验服并佩戴一次性手套和口罩操作。
联系人:高小姐
手 机:13585831301
Q Q:3004967995
座 机:021-59541103
传 真:021-60443211
地 址:上海嘉定区嘉罗公路1661